newsfilter
← Latest News
PR Newswire·

Elevation Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023Announced pipeline prioritization and realignment of